Background {#Sec1}
==========

Porcine circovirus 2 (PCV2) is the major etiological agent that causes PCV2-associated diseases (PCVAD) in growing pigs. This includes post-weaning multi-systemic wasting syndrome (PMWS), porcine dermatitis and nephropathy syndrome (PDNS), porcine respiratory disease complex (PRDC), congenital tremors type II (CT) and reproductive failure \[[@CR1]--[@CR4]\]. PCV2 is a small, single-stranded, non-enveloped, circular DNA virus containing a genome of 1766--1768 nt \[[@CR5]\]. The PCV2 genome contains 11 open reading frames (ORFs) \[[@CR5]\]. Five proteins, encoded by ORF1 to ORF5, are currently studied and recognized as the functional proteins of PCV2 \[[@CR6]--[@CR11]\]. Among these, the main ORF1 and ORF2 were identified as genes encoding viral replicase (Rep and Rep') and capsid protein, respectively \[[@CR6], [@CR11]\]*.*

It has been shown that PCV2 is continuously evolving through point mutation and genome recombination, which can lead to some new antigenic variant strains and it is known that new PCV2 variant strains are emerging \[[@CR12]--[@CR14]\]. Phylogenetic analyses of the complete genome and ORF2 region of PCV2 isolates worldwide have shown that PCV2 could be divided into eight distinct genotypes. These have been named PCV2a, PCV2b, PCV2c, PCV2d, PCV2e, PCV2f, PCV2g and PCV2h according to a new genotyping methodology protocol \[[@CR15]\]*.* PCV2a, PCV2b and PCV2d have been circulating worldwide and shown to have five (2A--E), three (1A--C) and two sub-genotypes (2d-1 and 2d-2) \[[@CR13], [@CR16]\], respectively, while the presence of PCV2c has only been reported in Denmark and Brazil \[[@CR16]--[@CR18]\]. PCV2e has been identified in pigs from China, Thailand, USA and Mexico \[[@CR19]--[@CR22]\]. Amongst all PCV2 genotypes, PCV2a was the predominant strain prior to 2000 and then there appeared to be a global genetic shift from PCV2a to PCV2b with the latter being the predominant genotype seen in the past ten years \[[@CR18], [@CR19], [@CR23], [@CR24]\]. Recently, there is a number of reports which suggest that there is an ongoing genotype shift occurring from PCV2b to PCV2d \[[@CR13], [@CR25]\]. In 2010, a variant PCV2 mutant strain designated mPCV2b, now grouped in PCV2d, with an elongation of its ORF2 by one amino acid, lysine (K), was identified in several PCVAD cases in China and other countries and recent studies showed that the prevalence rate of mPCV2b appears to have increased in China and a similar trend is evident in the U.S.A \[[@CR13], [@CR23], [@CR26], [@CR27]\].

Although there is increasing use of killed or subunit vaccines against PCV2 in pigs, the prevalence of PCV2 in China is still on the rise. Guangxi Province is one of the biggest pig breeding regions in China. The aim of this study was to investigate the prevalence and genetic variation of PCV2 in China using strains observed in the pig population from 2002 to 2016. Our findings revealed that PCV2d has becoming the predominating virus since 2014. Overall, this study helps to elucidate important aspects of the molecular genetic evolution of PCV2 and this is a prerequisite for the future development of effective disease control and prevention strategies for the spread of this virus.

Results {#Sec2}
=======

Prevalence of PRRSV in Guangxi Province, China from 2002 to 2016 {#Sec3}
----------------------------------------------------------------

Of the 371 filed samples collected from the clinical diseased and health pigs between 2002 and 2016 in the Guangxi Province of China, 181 samples (48.8%) were positive for PCV2, as determined by specific PCR. These results indicate that PCV2 is distributed widely among swine populations in the Guangxi Province.

Sequence and phylogenetic analyses of the ORF2 gene of PCV2 {#Sec4}
-----------------------------------------------------------

To explore the genetic relationship and evolution of PCV2 from 2002 to 2016, 95 of 181 PCV2 positive samples were used for genome amplification and sequencing and phylogenetic analysis was carried out based on the sequences of the ORF2 gene of 95 PCV2 isolates with reference sequences. The results showed that the complete genomes of all 95 strains were 1767 or 1768 bp in length as shown in Table [1](#Tab1){ref-type="table"}. Forty of the 95 ORF2 nucleotide sequences were 702 bp in length, encoding a Cap protein of 233 amino acid residues. Forty five of the 95 ORF2 nucleotide sequences were 705 bp, encoding a Cap protein of 234 amino acid residues. These strains are also known as mutant PCV2 (mPCV2), which has a codon shift from TTA to CTT in ORF2, resulting in a mutation of the stop codon (from UAA to AAG) in the ORF2, leading to an extended lysine (K) residue encoded by AAG or AAA.Table 1The designations, clinical signs, genotypes, GenBank accession numbers and other characteristics of the PCV2 genomes sequenced in this studyDesignationGeographic originClinical historyTissueYear of the collectionGenotypeGenBank NoGenome size (nt)ORF21GXNN0201NanningPMWSInguinal lymph node2002PCV2b-1BMH46541517677022GXGG0201GuigangPMWSInguinal lymph node2002PCV2eMH46548317687023GXNN0202NanningPMWSInguinal lymph node2002PCV2b-1AMH46541617677024GXNN0203NanningPMWSInguinal lymph node2002PCV2b-1BMH46541717677025GXBH0301BeihaiPMWSInguinal lymph node2003PCV2b-1AMH48174817677026GXNN0301NanningPMWSInguinal lymph node2003PCV2dMH46545717677057GXYL0601YulinPMWSInguinal lymph node2006PCV2b-1BMH46543317677028GXWZ0602WuzhouPMWSInguinal lymph node2006PCV2b-1AMH46543217677029GXNN0603NanningPMWSInguinal lymph node2006PCV2b-1BMH465418176770210GXHZ0708HezhouPMWSInguinal lymph node2007PCV2b-1BMH465407176770211GXHZ0709HezhouPMWSInguinal lymph node2007PCV2b-1BMH465408176770212GXHZ0710HezhouPMWSInguinal lymph node2007PCV2b-1AMH465409176770213GXBH0801BeihaiPMWSInguinal lymph node2008PCV2b-1BMH465398176770214GXLB0802WuxuanPMWSInguinal lymph node2008PCV2dMH465449176770515GXGG0802GuigangPMWSInguinal lymph node2008PCV2b-1BMH465404176770216GXNN0803NanningPMWSInguinal lymph node2008PCV2b-1AMH465419176770217GXNN0804NanningPMWSInguinal lymph node2008PCV2dMH465458176770518GXCZ0805ChongzuoPMWSInguinal lymph node2008PCV2b-1BMH465402176770219GXGG0805GuigangPMWSInguinal lymph node2008PCV2dMH465444176770520GXNN0806NanningPMWSInguinal lymph node2008PCV2b-1BMH465420176770221GXNN0901aNanningNo signsInguinal lymph node2009PCV2b-1BMH465421176770222GXNN0901bNanningNo signsInguinal lymph node2009PCV2dMH465459176770523GXNN0902NanningNo signsInguinal lymph node2009PCV2b-1BMH465422176770224GXNN0904NanningAbortionAborted fetus2009PCV2dMH465460176770525GXBH1008BeihaiPMWSInguinal lymph node2010PCV2b-1BMH465399176770226GXLZ1103aLiuzhouNo signsInguinal lymph node2011PCV2b-1BMH465414176770227GXLZ1103bLiuzhouNo signsInguinal lymph node2011PCV2dMH465452176770528GXLZ1208aLiuzhouNo signsInguinal lymph node2012PCV2hMH465453176770529GXYL1208YulinNo signsInguinal lymph node2012PCV2hMH465473176770530GXLB1212aLaibinNo signsInguinal lymph node2012PCV2eMH465485176870231GXLB1212bLaibinNo signsInguinal lymph node2012PCV2dMH465450176770532GXLB1212cLaibinNo signsInguinal lymph node2012PCV2eMH465486176870233GXGG1212GuigangNo signsInguinal lymph node2012PCV2dMH465405176870234GXLZ1208bLiuzhouNo signsInguinal lymph node2012PCV2dMH465454176770535GXLZ1208cLiuzhouNo signsInguinal lymph node2012PCV2dMH465455176770536GXGG1208GuigangPMWSInguinal lymph node2012PCV2eMH465484176870237GXNN1209aNanningPMWSInguinal lymph node2012PCV2b-1BMH465423176770238GXNN1209bNanningPMWSInguinal lymph node2012PCV2b-1BMH465424176770239GXYL1304YulinPMWSInguinal lymph node2013PCV2b-1BMH465434176770240GXNN1304aNanningPMWSInguinal lymph node2013PCV2dMH465461176770541GXNN1304bNanningPMWSInguinal lymph node2013PCV2b-1BMH465425176770242GXGG1305GuigangPMWSInguinal lymph node2013PCV2b-1BMH465406176770243GXYL1305YulinPMWSInguinal lymph node2013PCV2b-1BMH465435176770244GXGG1306GuigangPMWSInguinal lymph node2013PCV2dMH465445176770545GXYL1307aYulinPMWSInguinal lymph node2013PCV2dMH465474176770546GXYL1307bYulinPMWSInguinal lymph node2013PCV2eMH465490176870247GXYL1307cYulinPMWSInguinal lymph node2013PCV2dMH465475176770548GXYL1307dYulinPMWSInguinal lymph node2013PCV2b-1BMH465436176770249GXYL1310YulinPMWSInguinal lymph node2013PCV2b-1BMH465437176770250GXNN1312NanningPMWSInguinal lymph node2013PCV2b-1BMH465426176770251GXGG1312aGuigangPMWSInguinal lymph node2013PCV2dMH465446176770552GXGG1312bGuigangPMWSInguinal lymph node2013PCV2dMH465447176770553GXBS1401BaisePMWSInguinal lymph node2014PCV2dMH465439176770554GXYL1401YulinPMWSInguinal lymph node2014PCV2dMH465476176770555GXYL1403aYulinPMWSInguinal lymph node2014PCV2dMH465477176770556GXYL1403bYulinPMWSInguinal lymph node2014PCV2dMH465478176770557GXYL1405YulinPMWSInguinal lymph node2014PCV2dMH465479176770558GXLB1405LaibinPMWSInguinal lymph node2014PCV2b-1BMH465410176770259GXLZ1406LiuzhouPMWSInguinal lymph node2014PCV2dMH465456176770560GXNN1406NanningPMWSInguinal lymph node2014PCV2b-1BMH465427176770261GXYL1408YulinPMWSInguinal lymph node2014PCV2eMH465491176770562GXNN1409aNanningPMWSInguinal lymph node2014PCV2dMH465462176770563GXNN1409bNanningPMWSInguinal lymph node2014PCV2eMH465487176870264GXYL1409YulinPMWSInguinal lymph node2014PCV2b-1BMH465438176770265GXYL1410YulinPMWSInguinal lymph node2014PCV2dMH465480176770566GXNN1410aNanningPMWSInguinal lymph node2014PCV2dMH465463176770567GXCZ1410ChongzuoPMWSInguinal lymph node2014PCV2b-1BMH465403176770268GXNN1410bNanningPMWSInguinal lymph node2014PCV2eMH465488176870269GXNN1410cNanningPMWSInguinal lymph node2014PCV2dMH465464176770570GXBS1410BaisePMWSInguinal lymph node2014PCV2dMH465440176770571GXFC1501FangchenggangPMWSlymph node2015PCV2dMH465443176770572GXNN1501NanningNo signsLung, spleen, lymph node2015PCV2dMH465465176770573GXNN1503NanningNo signsLung, spleen, lymph node2015PCV2dMH465466176770574GXNN1504NanningNo signsLung, spleen, lymph node2015PCV2dMH465467176770575GXCZ1510aChongzuoPMWSlymph node2015PCV2dMH465441176770576GXCZ1510bChongzuoPMWSlymph node2015PCV2dMH465442176770577GXHC1511HechiNo signsLung, spleen, lymph node2015PCV2dMH465448176770578GXNN1511NanningNo signsLung, spleen, lymph node2015PCV2b-1BMH465428176770279GXLB1511aLaibinNo signsLung, spleen, lymph node2015PCV2b-1BMH465411176770280GXLB1511bLaibinNo signsLung, spleen, lymph node2015PCV2b-1BMH465412176770281GXLB1511cLaibinPMWSLung, spleen, lymph node2015PCV2b-1BMH465413176770282GXYL1512LaibinPMWSLung, spleen, lymph node2015PCV2dMH465481176770583GXQZ1601QinzhouPMWSlymph node2016PCV2dMH465472176770584GXNN1602NanningPMWSLung, lymph node2016PCV2dMH465468176770585GXNN1603aNanningPMWSlymph node2016PCV2dMH465469176770586GXNN1603bNanningPMWSLung2016PCV2b-1BMH465429176770287GXNN1604aNanningNo signsLung, spleen, lymph node2016PCV2aMH465489176870288GXNN1604bNanningNo signsLung, spleen, lymph node2016PCV2b-1BMH465430176770289GXLB1606LaibinPMWSLung, spleen, lymph node2016PCV2dMH465451176770590GXBS1607aBaisePMWSLung, spleen, lymph node2016PCV2eMH465400176770291GXBS1607bBaisePMWSLung, spleen, lymph node2016PCV2eMH465401176770292GXYL1607YulinPMWSLung, spleen, lymph node2016PCV2dMH465482176770593GXNN1612aNanningPMWSspleen2016PCV2dMH465470176770594GXNN1612bNanningNo signslymph node2016PCV2dMH465471176770595GXNN1612cNanningNo signsLung, spleen, lymph node2016PCV2b-1BMH4654311767702

Comparisons of the complete genomic sequence revealed 96.6% identity between PCV2a strains and the reference PCV2a strains (Table [2](#Tab2){ref-type="table"}). The nucleotide sequence identity between PCV2b strains and reference PCV2b strains was 97.0--99.4%. The nucleotide sequence identity between PCV2d strains and the reference PCV2d strains was 97.1--99.9% and the nucleotide sequence identity between PCV2e strains and the reference PCV2e strains was 97.6\~99.4% (Table [2](#Tab2){ref-type="table"}). To investigate variations in the deduced amino acid sequences of ORF2 gene products, the amino acid sequences of 95 PCV2 strains including some representative strains were aligned. The results showed that there are five major regions of variation among the PCV2 strains. These include residues 57--91, 121--151, 181--191, 206--215 and 230--233 (Fig.[1](#Fig1){ref-type="fig"}). One of the 96 strains has a typical TNKISI motif present in PCV2a. 39 of the 96 strains have typical S/PNPRSV and A/TGIE motifs present in PCV2b and 43/95 strains have SNPLTV and TGID motifs present in most of the PCV2d. PCV2e strains have a typical TNKISI motif which are also present in the PCV2a strains. Compared with PCV2a, PCV2e have specific substitutions at positions 47 (T to S), 72 (R to L), 131 (P to F), 187 (L to I) and 191(R to K). PCV2h strains have a typical SNPLTV motif which is present in most of the PCV2d strains. But the motif, TGID, was changed to SAID. Specific aa changes in the reported antibody epitope regions and immune-dominant decoy epitope regions (57--91, 181--191 and 230--233) of the Cap protein were found in some strains. Moreover, specific aa changes at positions 133--135 were also identified in some strains. As a result of a mutation at the stop codon, 45 of the 96 strains had an extended lysine (K) residue encoded by AAG or AAA.Table 2Comparison of the complete genomic sequences of the different PCV2 strains examined in this studyKX828215 (PCV2a)New strain (PCV2a)AY916791 (PCV2b)New strains (PCV2b)KJ187306 (PCV2d)New strains (PCV2d)EF524526 (PCV2e)New strains (PCV2e)JX506730 (PCV2h)New strains (PCV2h)EU148503 (PCV2c)LC004750 (PCV2f)JX099786 (PCV2g)KX828215 (PCV2a)100.096.695.295.1\~95.594.994.5\~95.496.495.3\~96.796.095.9\~96.094.195.195.3New strain (PCV2a)100.094.694.4\~95.294.293.7\~94.596.695.2\~96.995.495.293.295.194.1AY916791 (PCV2b)100.097.0\~99.495.995.4\~96.395.593.9\~95.796.496.1\~96.294.895.695.5New strains (PCV2b)97.1\~100.095.9\~97.295.1\~97.395.2\~95.993.9\~97.296.0\~96.796.0\~97.294.5\~95.395.4\~96.095.5\~97.2KJ187306 (PCV2d)100.097.9\~99.795.094.2\~95.397.696.6\~96.794.595.596.6New strains (PCV2d)97.1\~99.894.3\~95.493.2\~95.796.0\~96.996.0\~97.193.9\~94.995.0\~95.996.2\~97.0EF524526 (PCV2e)100.097.6\~99.495.995.5\~95.694.196.194.7New strains (PCV2e)96.8\~99.794.5\~96.394.9\~96.092.8\~94.294.9\~97.493.8\~95.0JX506730 (PCV2h)100.098.495.096.095.8New strains (PCV2h)99.794.8\~94.996.1\~96.296.8\~96.9EU148503 (PCV2c)100.094.794.8LC004750 (PCV2f)100.095.5JX099786 (PCV2g)100.0Fig. 1Phylogenetic tree based on a comparison of 129 complete PCV2 genomic sequences, including the 95 sequences from this study and 34 PCV2 sequences originating from China and other countries. The tree was constructed using the Maximum Likelihood algorithm. The 34 reference strains which are representatives of all PCV2 genotypes are marked with a black circle

Phylogenetic analysis of the complete genome showed that current PCV2 strains in this study could be divided into PCV2a (1/95), PCV2b (39/95), PCV2d (43/95), PCV2e (10/95) and PCV2h (2/95), as shown in Fig. [2](#Fig2){ref-type="fig"}. The genotype PCV2b was further divided into PCV2b-1A (5/95) and PCV2b-1B (34/95). All 95 strains with a complete genome phylogeny have the same classification with respect to the ORF2-based phylogeny, except for two strains (GXNN0301and GXNN0604) which were clustered to PCV2g (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). Among the 5 sub-genotypes, PCV2b was dominant in the porcine population from 2002 to 2008. The newly identified sub-genotype, PCV2d, was found from 2003 and its presence has increased year by year. PCV2b and PCV2d are two predominant genetic groups which circulated in the Guangxi Province between 2009 and 2013 and PCV2d is the predominant genotype circulating in the swine population of this region since 2014 (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2The alignment of Cap for PCV2. A multiple alignment of PCV2 Cap was performed by Clustal W. The grey areas show the antibody recognition domains and the immune-dominant decoy epitope described previously \[[@CR30], [@CR31]\]. The boxes show the motifs of PCV2a, PCV2b and PCV2d which have been previously described \[[@CR13], [@CR28], [@CR29]\]Fig. 3The time distribution and genotype of the 95 PCV2 strains in this study

Discussion {#Sec5}
==========

In our previous study, 181 of the 371 (48.8%) samples collected were positive for PCV2, indicating that PCV2 is widely distributed among swine populations in Guangxi, China. There is extensive genetic variability in four major regions at amino acid positions 53--90, 121--136, 169--218 and 232--234. There are critical aa's within some signature motifs which are reported to be important for differentiation of the PCV2 genotype \[[@CR13], [@CR28], [@CR29]\] as well as regions such as antibody epitopes, immune-dominant decoy epitopes and key aa's which determine virulence \[[@CR30]--[@CR34]\] which were found in the Cap protein domains of some strains. ORF2 is the major structural protein of PCV2 that is believed to be involved in diverse functions such as receptor binding, host immune response and viral replication \[[@CR6], [@CR32]--[@CR34]\]. Therefore, a small number of mutations might result in antigenic variations or increased pathogenicity of the virus.

Full length genome and ORF2 based phylogenetic trees showed all these strains are present in 5 sub-genotypes (PCV2a, PCV2b, PCV2d, PCV2e and PCV2h). Global genetic analysis indicated that the PCV2 evolution trace was PCV2a to PCV2b to PCV2d \[[@CR13]\]. Many previous studies showed that genotype shift from PCV2a to PCV2b occurred in 2002 in mainland China and PCV2b has been the predominant genotype since then \[[@CR19], [@CR23], [@CR24]\]. A similar major shift from PCV2a to PCV2b has also occurred in many countries on a global scale prior to 2003 \[[@CR35], [@CR36]\]. Consistent with these previous studies, our study shows that only one strain (PCV2a) was found in 2016, suggesting a major shift from PCV2a to PCV2b had occurred in Guangxi Province in or prior to 2002. The PCV2b is the predominant genotype found between 2003 and 2011.

Many studies have indicated that the rapid genotype shift from PCV2a to PCV2b was related to the appearance of PMWS cases at the farmyard level together with an accompanying increase in clinical severity \[[@CR37]--[@CR39]\]. However, there are no significant difference in virulence between PCV2a and PCV2b-inoculated groups under experimental conditions \[[@CR40], [@CR41]\]. In this study, we also showed there was no significant relationship between the infection caused by PCV2b and PMWS cases (data not shown). Both PCV2a and PCV2b could be detected in the healthy pigs and in PWMS-affected pigs (Table [1](#Tab1){ref-type="table"}). Our results showed that PCV2b and PCV2d were the two predominant genetic groups circulating in southern China between 2008 and 2013. PCV2d was the predominant genotype seen since 2014, indicating that the process leading to the genotype shift from PCV2b to PCV2d had already begun at the province-wide scale in these subsequent years.

In 2010, a variant PCV2 mutant strain designated as mPCV2b, and now classified as PCV2d, was identified and the prevalence rate of mPCV2b appears to have increased both in China and the USA. In this study, a dramatic increase in detection of the PCV2d variant has been seen since 2014. Whether the PCV2d is more pathogenic in pigs is controversial. One study conducted by Guo et al. showed that mPCV2, now classified as PCV2d, induced more severe clinical, pathological, and virological manifestations than the genotypes PCV2a and PCV2b in conventional pigs \[[@CR23]\]. However, another study showed that there was no significant difference in pathogenicity between PCV2a/b and mPCV2 in caesarean-derived, colostrum-deprived pigs \[[@CR42]\].

In this study, we showed there was no significant relationship between the predominance of PCV2d and PMWS cases. Therefore, the pathogenicity of mPCV2 in pigs and the association between increased mPCV2 prevalence and its clinical manifestation in the field needs to be further studied.

Conclusions {#Sec6}
===========

This study reveals the complex genetic diversity of PCV2 and improves our understanding regarding the epidemiological trends of PCV2 sub-genotypes in China.

Methods {#Sec7}
=======

Sample collection, viral DNA extraction and PCV2 detection {#Sec8}
----------------------------------------------------------

Field samples (sera, lungs, lymph nodes and spleens) from commercial pig farms in different regions of Guangxi province between 2002 and 2016 were submitted to Laboratory of Animal infectious Diseases and Molecular Immunology, Guangxi University, Nanning for PCV2 testing. Total viral DNA was extracted directly from sera and tissue samples using Virus Genome Extract DNA kit according to the manufacturer's instructions (TIANGEN, Inc., Beijing, China). Viral DNAs were eluted in 50 μL of ddH~2~O and were stored at − 30 °C until used. All the samples were screened for PCV2 by PCR using primers (5′-CCGCGGGCTGGCTGAACTT-3′) and (5′-ACCCCCGCCACCGCTACC -3′). Thermal cycling conditions were 94 °C for 3 min, followed by 35 cycles of 94 °C for 40 s, 60 °C for 40s, 72 °C for 50 s, and a final elongation step at 72 °C for 10 min. Finally, the PCR products were analyzed using 1.0% agarose gel electrophoresis ultraviolet imaging. Positive samples were determined with 1154 bp amplified products. Positive amplicons were purified using E.Z.N.A.TM Gel Extraction Kit (OMEGA, USA) and were further cloned into pBST-IIvector (TIANGEN, Inc., Beijing, China) for nucleotide sequencing by using primer T~7~ or T~3~ (HuaDa Gene, Inc., China).

PCV2 amplification and sequence determination {#Sec9}
---------------------------------------------

PCV2 positive samples were used for full-length genome amplification and sequencing. The forward primer (5′ GAACCGCGGGCTGGCTGAACTTTTGAAAGT 3′) and reverse primer (5′ GCACCGCGGAAATTTCTGACAAACGTTACA 3′) were used for amplification of the full genome. PCR reaction conditions were 94 °C for 5 min, followed by 30 cycles of 94 °C for 1 min, 55 °C for 1 min, 72 °C for 2 min, and a final elongation step at 72 °C for 10 min. The PCR products were purified with E.Z.N.A.TM Gel Extraction Kit (OMEGA, USA) and cloned into a *pBST-II*vector (TIANGEN, Inc., Beijing, China). Positive clones were sequenced in both directions using universal primers T7 and SP6 promoter-specific primers (HuaDa Gene, Inc., China).

Phylogenetic tree analysis {#Sec10}
--------------------------

Differences of the amino acid sequences derived from the ORF2 gene of the 95 strains and representative isolates from China and other countries were analyzed and aligned using DNAstar software (DNASTAR Inc., Madison, WI, USA). MEGA version 6.0 was used to evaluate phylogenetic relationships by the Maximum Likelihood method with 1000 bootstrap replicates. A Maximum Likelihood phylogenetic tree was constructed including the 95 different complete genomes or ORF2 genes from this study and the complete genome or ORF2 gene sequences of the 34 representative isolates from China and other countries representative of all PCV2 genotypes, containing the considered PCV2 genotypes a, b, c, d, e, f, g and h. The sequences obtained in this study were submitted to the GenBank database under the accession numbers (MH465398\~MH465491 and MH481748).

Statistical analysis {#Sec11}
--------------------

PASW Statistics 18 software (PASW, Inc., an IBM Company, Chicago, IL) was used to perform χ~2~ test to evaluate the association of PCV2b and PCV2d with PMWS cases. *P* values of \< 0.05 were considered statistically significant.

Additional file
===============

 {#Sec12}

Additional file 1:Phylogenetic tree based on PCV2 ORF2 sequences**.** Phylogenetic tree based on a comparison of 129 PCV2 ORF2 sequences, including the 95 sequences from this study and 34 PCV2 sequences originating from China and other countries. The tree was constructed using the Maximum Likelihood algorithm. The 34 reference strains which are representatives of all PCV2 genotypes are marked with a black circle. (PPTX 203 kb)
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